4 Stocks Driving The Drugs Industry Higher

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Two out of the three major indices are trading lower today with the Dow Jones Industrial Average ( ^DJI) trading down 47 points (-0.3%) at 15,521 as of Wednesday, July 24, 2013, 12:50 PM ET. The NYSE advances/declines ratio sits at 716 issues advancing vs. 2,228 declining with 95 unchanged.

The Drugs industry currently sits down 0.6% versus the S&P 500, which is down 0.3%. Top gainers within the industry include Novo Nordisk A/S ( NVO), up 1.0%, and Biogen Idec ( BIIB), up 0.6%. On the negative front, top decliners within the industry include Regeneron Pharmaceuticals ( REGN), down 1.0%, and Teva Pharmaceutical Industries ( TEVA), down 0.5%.

TheStreet would like to highlight 4 stocks pushing the industry higher today:

4. Illumina ( ILMN) is one of the companies pushing the Drugs industry higher today. As of noon trading, Illumina is up $8.60 (11.7%) to $82.37 on heavy volume. Thus far, 3.1 million shares of Illumina exchanged hands as compared to its average daily volume of 1.3 million shares. The stock has ranged in price between $78.78-$83.23 after having opened the day at $79.45 as compared to the previous trading day's close of $73.77.

Illumina, Inc. develops, manufactures, and markets life science tools and integrated systems for the analysis of genetic variation and biological function in North America, Europe, Latin America, the Asia-Pacific, the Middle East, and South Africa. Illumina has a market cap of $9.3 billion and is part of the health care sector. Shares are up 34.4% year to date as of the close of trading on Tuesday. Currently there are 8 analysts that rate Illumina a buy, no analysts rate it a sell, and 8 rate it a hold.

TheStreet Ratings rates Illumina as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, good cash flow from operations, largely solid financial position with reasonable debt levels by most measures, solid stock price performance and expanding profit margins. We feel these strengths outweigh the fact that the company has had sub par growth in net income. Get the full Illumina Ratings Report now.

3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

3. As of noon trading, Valeant Pharmaceuticals International ( VRX) is up $0.99 (1.1%) to $91.48 on average volume. Thus far, 965,334 shares of Valeant Pharmaceuticals International exchanged hands as compared to its average daily volume of 2.0 million shares. The stock has ranged in price between $90.92-$91.88 after having opened the day at $91.12 as compared to the previous trading day's close of $90.49.

Valeant Pharmaceuticals International, Inc., a specialty pharmaceutical company, develops, manufactures, and markets pharmaceutical products and medical devices in the areas of neurology, dermatology, and branded generics. Valeant Pharmaceuticals International has a market cap of $30.2 billion and is part of the health care sector. Shares are up 51.4% year to date as of the close of trading on Tuesday. Currently there are 9 analysts that rate Valeant Pharmaceuticals International a buy, 1 analyst rates it a sell, and 3 rate it a hold.

TheStreet Ratings rates Valeant Pharmaceuticals International as a hold. The company's strengths can be seen in multiple areas, such as its robust revenue growth, solid stock price performance and good cash flow from operations. However, as a counter to these strengths, we also find weaknesses including feeble growth in the company's earnings per share, deteriorating net income and generally higher debt management risk. Get the full Valeant Pharmaceuticals International Ratings Report now.

3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

2. As of noon trading, Eli Lilly and Company ( LLY) is up $1.33 (2.6%) to $52.32 on heavy volume. Thus far, 5.3 million shares of Eli Lilly and Company exchanged hands as compared to its average daily volume of 5.4 million shares. The stock has ranged in price between $51.75-$52.68 after having opened the day at $52.05 as compared to the previous trading day's close of $50.99.

Eli Lilly and Company discovers, develops, manufactures, and sells pharmaceutical products worldwide. Eli Lilly and Company has a market cap of $57.0 billion and is part of the health care sector. Shares are up 2.7% year to date as of the close of trading on Tuesday. Currently there are 6 analysts that rate Eli Lilly and Company a buy, 2 analysts rate it a sell, and 7 rate it a hold.

TheStreet Ratings rates Eli Lilly and Company as a buy. The company's strengths can be seen in multiple areas, such as its increase in net income, largely solid financial position with reasonable debt levels by most measures, notable return on equity, reasonable valuation levels and expanding profit margins. We feel these strengths outweigh the fact that the company shows weak operating cash flow. Get the full Eli Lilly and Company Ratings Report now.

3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

1. As of noon trading, Gilead ( GILD) is up $0.59 (1.0%) to $59.71 on average volume. Thus far, 5.2 million shares of Gilead exchanged hands as compared to its average daily volume of 11.2 million shares. The stock has ranged in price between $59.05-$60.13 after having opened the day at $59.71 as compared to the previous trading day's close of $59.12.

Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes human therapeutics for the treatment of life threatening diseases in North America, Europe, and Asia. Gilead has a market cap of $91.1 billion and is part of the health care sector. Shares are up 62.6% year to date as of the close of trading on Tuesday. Currently there are 18 analysts that rate Gilead a buy, no analysts rate it a sell, and 2 rate it a hold.

TheStreet Ratings rates Gilead as a buy. The company's strengths can be seen in multiple areas, such as its increase in net income, revenue growth, solid stock price performance, reasonable valuation levels and good cash flow from operations. Although the company may harbor some minor weaknesses, we feel they are unlikely to have a significant impact on results. Get the full Gilead Ratings Report now.

3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

If you are interested in one of these 4 stocks, ETFs may be of interest. Investors who are bullish on the drugs industry could consider SPDR S&P Pharmaceuticals ETF ( XPH) while those bearish on the drugs industry could consider ProShares UltraShort Nasdaq Biotech ( BIS).

null

More from Markets

Italian Bonds Slump as Government Mulls Anti-Euro Finance Minister

Italian Bonds Slump as Government Mulls Anti-Euro Finance Minister

Global Stocks Hold Gains as North Korea Response on Talks Soothes Nerves

Global Stocks Hold Gains as North Korea Response on Talks Soothes Nerves

Canopy Growth Lets Down Eager Pot Investors; PayPal Keeps Dominating -- ICYMI

Canopy Growth Lets Down Eager Pot Investors; PayPal Keeps Dominating -- ICYMI

Dow, S&P 500 and Nasdaq Tumble After Trump Calls Off North Korea Summit

Dow, S&P 500 and Nasdaq Tumble After Trump Calls Off North Korea Summit

Inside Carnival's Mind Blowing New Horizon Cruise Ship (Video)

Inside Carnival's Mind Blowing New Horizon Cruise Ship (Video)